Abstract
Background: Measles–mumps–rubella (MMR) vaccine replaced monovalent measles vaccine in the routine childhood vaccination schedule in Israel in December 1988, primarily to achieve the elimination of the congenital rubella syndrome. In this observational study, we report on changes in reported mumps incidence in Israel from the time of the introduction of MMR vaccine until the end of 1998. Methods: The report is based upon passive national surveillance of mumps incidence, which has been notifiable in Israel since 1977. Results: Reported mumps incidence in Israel is now less than 2% the pre-vaccine incidence. Conclusions: In the decade since the introduction of routine mumps vaccination in 1-year-olds in Israel, mumps control has been achieved. Although small outbreaks occur and may continue to occur in future years, because of undervaccination of children, primary vaccine failure and waning immunity, it can tentatively be said that mumps is no longer a public health problem in Israel.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Holmes SJ. Mumps. In: Evans A (ed), Viral infections of humans, epidemiology and control, 4th edn. New York: Plenum, 1997: 531–550.
Hope-Simpson RE. Infectiousness of communicable diseases in the household. Lancet 1953; 2: 549–554.
Centers for Disease Control and Prevention. Measles, mumps and rubella — vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps. MMWR 1998; 47(RR-8): 6–7.
Christie AB. Mumps (epidemic parotitis). In: Christie AB (ed), Infectious diseases, 4th edn. Edinburgh: Churchill Livingstone, 1987: 629–654.
Cochi SL, Wharton M, Plotkin SA. Mumps vaccine. In: Plotkin SA, Mortimer EA (eds), Vaccines, 2nd edn. Philadelphia: WB Saunders, 1994: 277–302.
Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1996. MMWR 1996; 45: 45.
Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the post-vaccine era. J Infect Dis 1988; 158: 1253–1260.
Hersh BS, Fine PEM, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119: 187–193.
Cheek JE, Baron R, Atlas H, Wilson DL, Crider RD. Mumps outbreak in a highly vaccinated school population: Evidence for large-scale vaccination failure. Arch Pediatr Adolesc Med 1995; 149: 774–778.
Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169: 77–82.
White CE, Kaplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75: 739–744.
Berger SA, Ginsberg GM, Slater PE. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants. Isr J Med Sci 1990; 26: 74–80.
Slater PE, Costin C. Infectious disease and mortality surveillance in Israel in peace and war. Public Health Reviews 1993; 20: 280–284.
Noah ND. Strategy of immunization. Community Med 1983; 5: 140–147.
Slater PE, Roitman M, Leventhal A, Anis E. Control of rubella in Israel, progress and challenge. Public Health Rev 1996; 24: 183–192.
Centers for Disease Control. Recommendations of the International Task Force for Disease Eradication. MMWR 1993; 42(RR16): 1–25.
Global Disease Elimination and Eradication as Public Health Strategies. Bull WHO 1998; 76(Suppl 2).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Slater, P.E., Anis, E. & Leventhal, A. The control of mumps in Israel. Eur J Epidemiol 15, 765–767 (1999). https://doi.org/10.1023/A:1007663429371
Issue Date:
DOI: https://doi.org/10.1023/A:1007663429371